Compare Amylx Pharmaceuticals Inc (AMLX) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Taskus Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Taskus Inc trades at $5.46 (market cap $495.44M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 4× Taskus Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | TASK | |
|---|---|---|
Market Cap | $1.98B | $495.44M |
Sector | Health | Technology |
52-Week High | $18.70 | $18.21 |
52-Week Low | $7.64 | $4.57 |
Enterprise Value | $1.70B | $891.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
TaskUs (TASK) trades at $5.41, up 2.66% today, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals with a P/E of 4.79 and net income margin of 8.7%, while recent Q1 2026 earnings missed expectations. Revenue grew to $1.18 billion in 2025, and the company appointed a new CFO in June 2026.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. However, risks include recent earnings miss, competitive pressures in digital services, and potential market volatility. Analyst sentiment is mixed with 55% buy ratings but cautious technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
